For personal use only

ASX/ Media Release
19 April 2017

OncoSil receives Institutional Review Board Approval from MD Anderson Cancer Center for Pancreatic Clinical Study Programme

Sydney, Australia, 19 April 2017: OncoSil Medical Limited (ASX: OSL) **(OncoSil Medical** or the **Company)** a medical device company focused on localized treatments for patients with pancreatic and liver cancer, is pleased to announce that it has received approval from the Institutional Review Board (IRB) of the MD Anderson Cancer Center at the University of Texas for its global clinical study program in pancreatic cancer.

MD Anderson is one of the world's leading cancer centers, and the first to grant IRB approval in the US for the company's global clinical study.

IRB approval is the final step for US hospitals to agree to participate in a clinical study and recruit and treat patients under the agreed study protocols. MD Anderson will now finalise site initiation and complete final training before first patient recruitment which is anticipated to occur in May.

In addition to MD Anderson, other participating study centers in the US include:

- The Johns Hopkins University Hospital, University Medical School in Maryland, USA – *joint lead US study center*
- The Moffitt Cancer Center, Tampa, USA
- Northwestern Memorial Hospital, Chicago, USA
- Cedars-Sinai Hospital, Los Angeles, USA

The formal IRB process has commenced at all US participating study centres and is on-going.

OncoSil Medical CEO Daniel Kenny said:

"We are pleased to make continued progress with our clinic operations in the US, and are encouraged by the engagement of our study center partners in working toward the treatment of patients as part of this important global study in pancreatic cancer."

- ENDS -

Company	Media
Mr Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au T: +61 2 9223 3344	**Ben Walsh** WE Buchan E: bwalsh@buchanwe.com.au M: 0411 520 012

About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorous-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical studies with encouraging results on tolerability, safety and efficacy. A CE Mark application to commercially sell OncoSil™ in the European Union (EU) is under review with commercial launch, subject to approval.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval. Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds $1b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to $1.4b by 2019.

For personal use only

ONCOSIL MEDICAL LIMITED ABN 89 113 824 141 ASX | OSL
Suite 402, Level 4, 50 Berry Street, North Sydney NSW 2000 AUSTRALIA
TELEPHONE +61 2 9223 3344 FACSIMILE +61 2 9252 3988
WEB www.oncosil.com.au